<p>(A) Per protocol analysis. (B) Intention-to-treat analysis. VL, viral load; RAL, raltegravir; DRV/r, ritonavir-boosted darunavir; LPV/r, ritonavir-boosted lopinavir; TVD, fixed dose of tenofovir/emtricitabine.</p
International audienceAIM: Dolutegravir (DTG) and rilpivirine (RPV) dual therapy is now recommended ...
International audienceAIM: Dolutegravir (DTG) and rilpivirine (RPV) dual therapy is now recommended ...
<p>* HIV RNA < 400 copies/ml;</p><p><sup>¶</sup>HIV RNA ≥ 400 copies/ml;</p><p>3TC (lamiduvine), D4T...
<p>Proportion of patients with HIV-1 RNA < 50 copies/mL (ITT FDA snapshot analysis) at weeks 48, 96 ...
<p>Proportion of subjects with plasma HIV-1 RNA<48 copies/mL and <200 copies/mL using the Intention-...
Proportion of participants with plasma HIV-1 RNA <50 c/mL through week 48 by intention to treat (mis...
<p>Percentage indicated shows subjects with HIV-1 RNA <50 copies/mL at week 48. Studies that were ra...
<p>Abbreviations: LLV, low-level viraemia; VF, virological failure; VL, viral load; NRTIs, nucleosid...
Aim: In this study, we retrospectively evaluated the demographic features and the results of human i...
bstract OBJECTIVES: To determine factors associated with beginning antiretroviral therapy and with t...
a<p>Values represent n (% with characteristic) or median (interquartile range).</p>b<p>Patient had a...
Proportion of responders with HIV-1 RNA <40 copies/mL (Week 24 snapshot) (mITT).</p
Description of BBs (a) and third drugs (b) of the 571 patients included in the study. Data are expre...
International audienceAIM: Dolutegravir (DTG) and rilpivirine (RPV) dual therapy is now recommended ...
International audienceAIM: Dolutegravir (DTG) and rilpivirine (RPV) dual therapy is now recommended ...
International audienceAIM: Dolutegravir (DTG) and rilpivirine (RPV) dual therapy is now recommended ...
International audienceAIM: Dolutegravir (DTG) and rilpivirine (RPV) dual therapy is now recommended ...
<p>* HIV RNA < 400 copies/ml;</p><p><sup>¶</sup>HIV RNA ≥ 400 copies/ml;</p><p>3TC (lamiduvine), D4T...
<p>Proportion of patients with HIV-1 RNA < 50 copies/mL (ITT FDA snapshot analysis) at weeks 48, 96 ...
<p>Proportion of subjects with plasma HIV-1 RNA<48 copies/mL and <200 copies/mL using the Intention-...
Proportion of participants with plasma HIV-1 RNA <50 c/mL through week 48 by intention to treat (mis...
<p>Percentage indicated shows subjects with HIV-1 RNA <50 copies/mL at week 48. Studies that were ra...
<p>Abbreviations: LLV, low-level viraemia; VF, virological failure; VL, viral load; NRTIs, nucleosid...
Aim: In this study, we retrospectively evaluated the demographic features and the results of human i...
bstract OBJECTIVES: To determine factors associated with beginning antiretroviral therapy and with t...
a<p>Values represent n (% with characteristic) or median (interquartile range).</p>b<p>Patient had a...
Proportion of responders with HIV-1 RNA <40 copies/mL (Week 24 snapshot) (mITT).</p
Description of BBs (a) and third drugs (b) of the 571 patients included in the study. Data are expre...
International audienceAIM: Dolutegravir (DTG) and rilpivirine (RPV) dual therapy is now recommended ...
International audienceAIM: Dolutegravir (DTG) and rilpivirine (RPV) dual therapy is now recommended ...
International audienceAIM: Dolutegravir (DTG) and rilpivirine (RPV) dual therapy is now recommended ...
International audienceAIM: Dolutegravir (DTG) and rilpivirine (RPV) dual therapy is now recommended ...
<p>* HIV RNA < 400 copies/ml;</p><p><sup>¶</sup>HIV RNA ≥ 400 copies/ml;</p><p>3TC (lamiduvine), D4T...